In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

Flavia Pichiorri, Dario Palmieri, Luciana De Luca, Jessica Consiglio, Jia You, Alberto Rocci, Tiffany Talabere, Claudia Piovan, Alessandro Lagana, Luciano Cascione, Jingwen Guan, Pierluigi Gasparini, Veronica Balatti, Gerard Nuovo, Vincenzo Coppola, Craig C. Hofmeister, Guido Marcucci, John C. Byrd, Stefano Volinia, Charles L. Shapiro & 2 others Michael A. Freitas, Carlo M. Croce

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCLtargeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.

Original languageEnglish
Pages (from-to)951-968
Number of pages18
JournalJournal of Experimental Medicine
Volume210
Issue number5
DOIs
Publication statusPublished - May 2013

Fingerprint

MicroRNAs
Breast Neoplasms
Guanosine
Nuclear Proteins
Drug Resistance
nucleolin
Therapeutics
Genes
Neoplasms

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Pichiorri, F., Palmieri, D., De Luca, L., Consiglio, J., You, J., Rocci, A., ... Croce, C. M. (2013). In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Journal of Experimental Medicine, 210(5), 951-968. https://doi.org/10.1084/jem.20120950

In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. / Pichiorri, Flavia; Palmieri, Dario; De Luca, Luciana; Consiglio, Jessica; You, Jia; Rocci, Alberto; Talabere, Tiffany; Piovan, Claudia; Lagana, Alessandro; Cascione, Luciano; Guan, Jingwen; Gasparini, Pierluigi; Balatti, Veronica; Nuovo, Gerard; Coppola, Vincenzo; Hofmeister, Craig C.; Marcucci, Guido; Byrd, John C.; Volinia, Stefano; Shapiro, Charles L.; Freitas, Michael A.; Croce, Carlo M.

In: Journal of Experimental Medicine, Vol. 210, No. 5, 05.2013, p. 951-968.

Research output: Contribution to journalArticle

Pichiorri, F, Palmieri, D, De Luca, L, Consiglio, J, You, J, Rocci, A, Talabere, T, Piovan, C, Lagana, A, Cascione, L, Guan, J, Gasparini, P, Balatti, V, Nuovo, G, Coppola, V, Hofmeister, CC, Marcucci, G, Byrd, JC, Volinia, S, Shapiro, CL, Freitas, MA & Croce, CM 2013, 'In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation', Journal of Experimental Medicine, vol. 210, no. 5, pp. 951-968. https://doi.org/10.1084/jem.20120950
Pichiorri, Flavia ; Palmieri, Dario ; De Luca, Luciana ; Consiglio, Jessica ; You, Jia ; Rocci, Alberto ; Talabere, Tiffany ; Piovan, Claudia ; Lagana, Alessandro ; Cascione, Luciano ; Guan, Jingwen ; Gasparini, Pierluigi ; Balatti, Veronica ; Nuovo, Gerard ; Coppola, Vincenzo ; Hofmeister, Craig C. ; Marcucci, Guido ; Byrd, John C. ; Volinia, Stefano ; Shapiro, Charles L. ; Freitas, Michael A. ; Croce, Carlo M. / In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. In: Journal of Experimental Medicine. 2013 ; Vol. 210, No. 5. pp. 951-968.
@article{2043b7360a6e4d7890de38fbd7817239,
title = "In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation",
abstract = "Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCLtargeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.",
author = "Flavia Pichiorri and Dario Palmieri and {De Luca}, Luciana and Jessica Consiglio and Jia You and Alberto Rocci and Tiffany Talabere and Claudia Piovan and Alessandro Lagana and Luciano Cascione and Jingwen Guan and Pierluigi Gasparini and Veronica Balatti and Gerard Nuovo and Vincenzo Coppola and Hofmeister, {Craig C.} and Guido Marcucci and Byrd, {John C.} and Stefano Volinia and Shapiro, {Charles L.} and Freitas, {Michael A.} and Croce, {Carlo M.}",
year = "2013",
month = "5",
doi = "10.1084/jem.20120950",
language = "English",
volume = "210",
pages = "951--968",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "5",

}

TY - JOUR

T1 - In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation

AU - Pichiorri, Flavia

AU - Palmieri, Dario

AU - De Luca, Luciana

AU - Consiglio, Jessica

AU - You, Jia

AU - Rocci, Alberto

AU - Talabere, Tiffany

AU - Piovan, Claudia

AU - Lagana, Alessandro

AU - Cascione, Luciano

AU - Guan, Jingwen

AU - Gasparini, Pierluigi

AU - Balatti, Veronica

AU - Nuovo, Gerard

AU - Coppola, Vincenzo

AU - Hofmeister, Craig C.

AU - Marcucci, Guido

AU - Byrd, John C.

AU - Volinia, Stefano

AU - Shapiro, Charles L.

AU - Freitas, Michael A.

AU - Croce, Carlo M.

PY - 2013/5

Y1 - 2013/5

N2 - Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCLtargeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.

AB - Numerous studies have described the altered expression and the causal role of microRNAs (miRNAs) in human cancer. However, to date, efforts to modulate miRNA levels for therapeutic purposes have been challenging to implement. Here we find that nucleolin (NCL), a major nucleolar protein, posttranscriptionally regulates the expression of a specific subset of miRNAs, including miR-21, miR-221, miR-222, and miR-103, that are causally involved in breast cancer initiation, progression, and drug resistance. We also show that NCL is commonly overexpressed in human breast tumors and that its expression correlates with that of NCL-dependent miRNAs. Finally, inhibition of NCL using guanosine-rich aptamers reduces the levels of NCL-dependent miRNAs and their target genes, thus reducing breast cancer cell aggressiveness both in vitro and in vivo. These findings illuminate a path to novel therapeutic approaches based on NCLtargeting aptamers for the modulation of miRNA expression in the treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84879585408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879585408&partnerID=8YFLogxK

U2 - 10.1084/jem.20120950

DO - 10.1084/jem.20120950

M3 - Article

VL - 210

SP - 951

EP - 968

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 5

ER -